Fractyl Health shares surge 17.31% after-hours after positive 6-month REVEAL-1 data show Revita maintains post-GLP-1 weight loss and glycemic control.

Fractyl Health surged 17.31% in after-hours trading following the release of positive 6-month REVEAL-1 clinical trial results for its Revita procedure. The study demonstrated that patients who discontinued GLP-1 therapy and underwent a single Revita treatment maintained stable weight (1.5% mean change) and glycemic control over six months, outperforming historical data showing ~10% weight regain post-GLP-1 discontinuation. The procedure exhibited excellent tolerability, with no serious adverse events, and aligned with Revita’s European real-world performance. The FDA Breakthrough Device designation for post-GLP-1 weight maintenance and upcoming 2026 data from the REMAIN-1 trial further bolstered investor optimism. The results position Revita as a potential non-drug alternative for long-term metabolic health management, addressing unmet needs in obesity treatment.